MORAb-202 is a novel investigational antibody drug conjugate (ADC) that uses a cathepsin-cleavable linker to combine investigational farletuzumab with the microtubule inhibitor payload, eribulin. Farletuzumab is a humanized antibody targeting folate receptor alpha (FRA) and has been studied in clinical trials in patients with FRA-expressing tumors. FRA expression is observed in a large number of cancers, including endometrial, gastric, non-small cell lung, ovarian and triple-negative breast, but is largely absent from normal tissue. Eribulin mesylate (Halaven®) is approved in the U.S. for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease, including an anthracycline and a taxane in either the adjuvant or metastatic setting.
Current Clinical Studies
MORAb-202-J081-101 Phase 1 Study (Active; recruiting)
The Phase 1 trial, which is being conducted in Japan, is a first-in-human, dose-escalation study evaluating the safety and preliminary efficacy of MORAb-202 in patients with solid tumors that express folate receptor alpha (FRA). Following completion of the dose-escalation phase used to establish initial safety and optimal dosing, additional subjects will be enrolled to further study safety and preliminary efficacy of MORAb-202 in select tumor types, including triple-negative breast and endometrial cancers.
The information contained herein is investigational and is not intended to make claims of safety or efficacy prior to approval by the FDA or other regulatory authorities. There is no guarantee that the agents described or their uses will be approved by the FDA or other regulatory authorities.